openPR Logo
Press release

Idiopathic pulmonary fibrosis (IPF): Market Outlook and Competitive Landscape Report (2020 to 2030)

05-14-2021 12:59 PM CET | Health & Medicine


Idiopathic pulmonary fibrosis (IPF) ? Market Outlook and Competitive Landscape Report (2020? 2030)

Idiopathic pulmonary fibrosis (IPF) ? Market Outlook and Competitive Landscape Report (2020? 2030)

LAPS Triple Agonist (HM15211) of Hanmi Pharmaceutical has granted Orphan drug designation for treating Idiopathic pulmonary fibrosis (IPF). Pulmonary fibrosis occurs in the interstitium, which is the lung tissue that provides the scaffolding for the alveoli. Fibrosis thickens the interstitium, making the alveoli stiff so that they are unable to fully expand and hold as much air as they normally should. This thickening also limits the passage of oxygen through the wall of the alveoli into the bloodstream.

Based on strong domain and business knowledge Thelansis Knowledge Partners has published the market insight report on idiopathic pulmonary fibrosis (IPF) to provide a clear understanding of disease area background, epidemiology, current and future competitions, the country-specific standard of care, and the complete market forecast for 2020 to 2030. Based on the Epidemiology study of Thelansis 330,056 patients are prevalent in 8 Major Markets (USA, EU5, Japan and China), out of which 183,924 patients will able to meet the treatment for the year 2021 for the same 8 major markets. Yet, there is extensive research is ongoing to come with therapies to bring ease in the IPF’s patients life. Thelansis forecasting team project the IPF market of 8 MM approx. USD 2.93 Bn for the year 2021 which expected to grow with a 9% CAGR to reach USD 7.23 Bn by the year 2030.

The Idiopathic pulmonary fibrosis (IPF) market insight report provides a comprehensive view of disease events, severity, identified and emerging biomarkers, Clinical Manifestations, progression, signs & symptoms, risk factors, pathogenesis, genetic basis and treatment guidelines with respect to different lines of therapy at country level. Comprehensive insight on patient segmentation based on mild, moderate and severity. Based on acute, chronic comorbid condition (Pulmonary, cardiovascular, Gastrointestinal, Endocrine/Metabolic and Mental problems), IPF patients distributions among age groups 6 to 10; 11 to 15; 16 to 20; 21 to 30; 31 to 40; 41 to 50; 51 to 60; 61 to 70; 71 to 80; and 81 has been provided into the epidemiology section of the study. However the current treatment market share, market uptake, attribute analysis with respect to the 16 most potential emerging therapies (Pemrevlumab, KD025, PRM151, Tipelukast, CC 90001, PBI-4050, TD139, GLPG 1690, GLPG 1205, VAY 736, TAS-115, ART-123, LT-1001, LT-1002, INOpulse, BMS 986263) has been provided under the market outlook section of the study covering 8 MM countries; the United States, EU5 (Germany, Spain, France, Italy, UK) Japan and China.

In terms of pharmacologic therapies, there are several pharmaceutical products are being approved as well as under different phases of development for the treatment. The key companies in to advance stage of developments are Roche, MediciNova, Galecto Biotech, Liminal BioSciences, Sanofi, Biogen, Fibrogen, Galapagos, Kadmon Corporation, Afferent Pharmaceuticals, GlaxoSmithKline, Boehringer Ingelheim, Vicore Pharma, Bristol-Myers Squibb, Pliant Therapeutics, Novartis, Asahi Kasei Pharma, etc. targeting Idiopathic pulmonary fibrosis (IPF). Looking at the current clinical development and assets progress card, fast development and robust product would bring a game-changing opportunity for the pharmaceutical company developing products around the treatment of IPF.

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published report across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial result throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

Contact Us:
+91(124) 404-1731

Gold Souk Mall, SECTOR 43, PHASE- 1, Gurugram, Haryana, India

Thelansis is a global Consulting and Market Research Report Company. Thelansis provides advisory services and top-quality market research solutions to Pharma and Biotech companies worldwide. We provide assistance on the entire spectrum of Healthcare Value-Chain ranging from assisting clients on asset prioritizations to sales optimization and life-cycle management.

Thelansis have an exceptional team of professionals operating from our corporate offices in the US and operational center based out of India. Our management team is passionate about building an organization that is known for the best-in-class business solutions. Our experience ranges from working with emerging Biotech to Blue-Chip Pharma Companies. Thelansis’ commitment reflects in every single project and market research report we work upon and we take pride in all the direct and in-direct contributions we make to our client’s revenue.

This release was published on openPR.

Permanent link to this press release:

Please set a link in the press area of your homepage to this press release on openPR. openPR disclaims liability for any content contained in this release.

You can edit or delete your press release Idiopathic pulmonary fibrosis (IPF): Market Outlook and Competitive Landscape Report (2020 to 2030) here

News-ID: 2284260 • Views: 612

More Releases for IPF

Idiopathic Pulmonary Fibrosis (IPF) Therapeutics Pipeline Analysis, 2017
The study analyzed that the IPF pipeline comprised of 104 drug candidates, of which 19 drugs are in the Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. There are various drugs that are being developed as novel and promising therapeutics for the treatment of IPF. Explore Full Report Description At@ As per the findings of research, it
Global Idiopathic Pulmonary Fibrosis (IPF) Treatment Market US$ 3.5 Billion by 2 …
The global idiopathic pulmonary fibrosis treatment market expected to reach US$ 3.5 billion by 2021, growing at CAGR 14.4% over the forecast period 2017-2021, owing to increasing drug prices and rapid approval of new treatments. Visit Idiopathic Pulmonary Fibrosis (IPF) Treatment Market by Treatment Type - Pharmacological Treatment (Pirfenidone (Esbriet), Nintedanib (Ofev), Generic Pirfenidone); Non-pharmacological Treatment (Oxygen Therapy, Pulmonary Rehabilitation, Mechanical Ventilation, Lung Transplantation, Other Non-Pharmacological Treatment); Patients by Disease Severity
Recent Release: Global Idiopathic pulmonary fibrosis (IPF) Market To 2023
MarketResearchReports.Biz presents this most up-to-date research on "Idiopathic pulmonary fibrosis (IPF)- Epidemiology Forecast To 2023" Idiopathic pulmonary fibrosis (IPF) - Epidemiology Forecast To 2023 provides an overview of the epidemiology trends of Idiopathic pulmonary fibrosis (IPF) in seven major markets (US, France, Germany, Italy, Spain, UK and Japan). It includes 10 years epidemiology historical and forecasted data of Idiopathic pulmonary fibrosis (IPF) prevalent or incident cases segmented by age, sex and
Idiopathic Pulmonary Fibrosis (IPF) Pipeline, A Novel Advancement for the Treatm …
The study analyzed that the IPF pipeline comprised of 97 therapeutic candidates, of which 15 are in Phase II stage of development. The lack of complete cure for IPF fuels the extensive research and development for the IPF therapeutic. Various drugs are being developed as novel and promising therapeutics for the treatment of IPF. Browse the Report Summary at: Insights on pipeline segments As per the findings of research, it was found
Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology and Market F …
DelveInsight is a leading Business Consultant and Market Research Firm which has become the knowledge partner for biotechnology and pharmaceutical companies by providing competitive intelligence information which aids them to strategize and discover the target areas & potential customers for their products. DelveInsight expertise has expanded from an initial focus on Pipeline & Marketed Reports to Market Forecasting and Epidemiology Reports. Idiopathic Pulmonary Fibrosis (IPF) - Market Insights, Epidemiology
IPF Organizing Two Industrial Trade Shows in Kolkata in November
IPFonline Ltd is organizing two concurrent industrial trade fairs in Kolkata from November 18th to November 21st 2010. 1. Engeetech - An industrial products, engineering and technology trade fair 2. BACE - A Building, Architecture, Construction and Engineering Products trade fair As of yesterday 152 exhibitors have committed to exhibit at Engeetech and over 75 have committed to exhibit at BACE. Both the trade fairs will be held concurrently at